83 results about "Angiotensin II" patented technology

A method is described for the prophylaxis of hypertension in a cat in need thereof. The method includes administration of an effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, wherein the prophylaxis of hypertension is a delay of onset of hypertension.

The invention discloses a human angiotensin II purity standard substance, the mass concentration of which is 0.8734 g / g, the relative expansion uncertainty of which is 1.8% and the expansion uncertainty of which is 0.016 g / g. The purity standard substance is prepared by the following steps: selecting human angiotensin II of which the nominal purity is greater than or equal to 99%; carrying out sequence analysis, mass spectrum qualitative identification and primary homogeneity detection to obtain a purity standard substance candidate; and performing uniformity test and stability investigation on the purity standard substance candidate through a mass balance method, performing valuing by adopting the mass balance method and an isotope dilution mass spectrometry, and performing uncertainty evaluation on the purity standard substance candidate to obtain the purity standard substance. The human angiotensin II purity standard substance is accurate and reliable in valuing result, has traceability, and can be used for human angiotensin II quantity value traceability, measurement result quality control and standard substance evaluation.

A method is described for the prophylaxis of hypertension in a cat in need thereof. The method includes administration of an effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, wherein the prophylaxis of hypertension is a delay of onset of hypertension.

The embodiment of the invention discloses an angiotensin II-1 type receptor polypeptide or a fusion compound and application of the angiotensin II-1 type receptor polypeptide or the fusion compound. The invention provides an angiotensin type 1 receptor polypeptide or fusion, which is coated in a solid phase material (porous plate, magnetic beads, agarose particles, latex particles and the like) and is used for detecting an antibody aiming at an angiotensin II-1 receptor in the body of a patient suffering from diseases such as eclampsia and the like. The compound can also be used for blocking the combination of autoantibodies in the bodies of pregnant women and angiotensin II-1 type receptors, and treating various cardiovascular diseases such as dilated cardiomyopathy, just-gauge disease, heart failure and the like.

The invention discloses a method for valuing a human angiotensin II purity standard substance. The method comprises the following steps: (1) selecting human angiotensin II with the purity of more than or equal to 99% as the purity standard substance; (2) determining the value of the human angiotensin II purity standard substance by adopting a mass balance method; (3) hydrolyzing the human angiotensin II purity standard substance, taking isotope labeled phenylalanine, isoleucine and valine as internal standards, and determining the value of the human angiotensin II purity standard substance by liquid chromatography-isotope dilution mass spectrometry; and (4) calculating the average value of the fixed value results of the mass balance method and the isotope dilution mass spectrometry to obtain the fixed value result of the human angiotensin II purity standard substance. According to the method for determining the value of the human angiotensin II purity standard substance provided by the invention, the value of the human angiotensin II purity standard substance is determined by adopting a mass balance method and a liquid chromatography-isotope dilution mass spectrometry, and the finally obtained value determination result of the Ang II purity standard substance is 0.8734 g / g, so that the method has traceability.

The invention relates to a construction method and application of a loneliness mouse model, and the method comprises the steps: placing an experimental mouse in an isolation region in a transparent acrylic isolation cover through an environment in which physical isolation and social deprivation stimulation coexist, forming a visually accessible but physically isolated social environment with five normal living mice, and continuously inducing chronic loneliness for 4 weeks. The effectiveness of the model is verified through a multi-dimensional evaluation system, including behavioristics (open field, elevated maze and three-box experiment), neuroendocrine (serum noradrenaline and angiotensin II), immune inflammatory factors (IL-1beta, IL-6, TNF-alpha and CCL5) and nerve activation (blue spot, almond nucleus, lateral nucleus septum, medial prefrontal cortex and center joint dorsal nucleus C-Fos staining) indexes. According to the intervention method, dynamic environment abundance and social stimulation are adopted, running wheels are arranged, a modular abundance device is arranged, and a social environment of new mice is introduced, so that pathological phenotypes caused by loneliness are reversed. And a systematic experiment tool is provided for exploring association of aloneness and diseases.

The invention discloses an application of berberine in preparation of a medicine for treating hypertension. Experiments prove that berberine can improve changes of intestinal pathology caused by angiotensin II, blood pressure is reduced by adjusting intestinal flora, especially increasing abundance of Ackermann mucilaginophile and remodeling cardiovascular system, and blood pressure comprises systolic pressure and diastolic pressure. The invention has important application value in treatment of hypertension.

The present invention discloses an exosome-based delivery vehicle for targeted delivery of an active substance to cancer cells and cancer stem cells. The delivery vehicle is obtained by a method including the steps of incubating monocytes in a culture medium containing a biologic to obtain dendritic cells, adding an active substance to the culture medium containing the dendritic cells to obtain an exosome-based delivery vehicle containing the active substance, and isolating the exosome-based delivery vehicle from the culture medium for targeted delivery of the active substance specific to cancer cells and cancer stem cells. The present invention also discloses a biologic for enhancing the specificity of the exosome-based delivery vehicle to cancer cells and cancer stem cells. The biologic includes granulocyte macrophage colony stimulating factor, interleukin-4, ionomycin, tumor necrosis factor alpha, IL1β, LPS, and angiotensin II.

The invention belongs to the technical field of biological medicine, and particularly relates to application of lycium ruthenicum anthocyanin in preparation of a blood pressure lowering product. The invention provides application of lycium ruthenicum anthocyanin in preparation of a product for reducing blood pressure. The lycium ruthenicum anthocyanin is found to have an antihypertensive effect, can protect target organs such as heart and kidney, alleviate organ injury and reduce TG and LDL levels so as to reduce the risk of cardiovascular diseases, and is in direct proportion to dosage. The lycium ruthenicum anthocyanin has a pharmacodynamic mechanism of lowering blood pressure, lowering the level of angiotensin converting enzyme (ACE), reducing secretion of angiotensin II (AngII) and aldosterone (ALD), and regulating excessive activation of an RAAS system; the level of nitric oxide (NO) is improved, and vascular tension is reduced; the method is related to reduction of the thickness of the middle layer of the vascular intima and improvement of aortic remodeling, and has the advantage of multi-link and multi-target integral adjustment.

The invention discloses application of ACSS2 as an action target in screening or preparing a medicine for preventing or treating virus-induced vascular remodeling diseases, and belongs to the field of biological medicine. It is found that by inhibiting ACSS2 gene expression or protein activity, Zika virus induced vascular smooth muscle cell phenotypic transformation can be remarkably reversed, and occurrence and development of angiotensin II / aminopropionitrile induced aortic aneurysm / dissection are relieved. The invention provides a siRNA sequence (SEQ ID NO.1-2) specifically targeting ACSS2 and a pharmaceutical composition containing the siRNA, and provides a novel treatment target and a precise intervention tool for virus-related vascular remodeling diseases.

The present invention relates to angiotensin II receptor antagonists and their use for the treatment of peripheral neuropathic pain. In particular, the present invention provides a compound of formula (IV) or a pharmaceutically acceptable salt or stereoisomer thereof, and their use for the treatment of peripheral neuropathic pain.

The invention discloses application of isobutyrate in construction of a heart failure cell model, and relates to the technical field of biology. By innovatively applying isobutyric acid or isobutyrate, a new heart failure cell model is constructed. The model treats myocardial cells by means of isobutyrate with the concentration of 0.5-5 mM, the heart failure phenotype can be efficiently induced, the effect of the concentration of 5 mM is optimal, expression of core heart failure marker genes such as Nppa, Nppb and Myh7 can be stably up-regulated, meanwhile, the area of the myocardial cells is remarkably increased, and the heart failure pathological characteristics are met. Compared with a traditional angiotensin II and other neurohormone induction model, the invention provides a non-neurohormone-dependent brand-new heart failure cell model construction path, focuses on metabolic disorder related heart failure inducements, makes up for the defect of single mechanism of the existing model, and provides a new heart failure cell model construction path. A unique tool is provided for researching myocardial damage caused by abnormal metabolism or intestinal flora metabolites.

The present invention relates to repurposing the use of angiotensin Converting Enzyme Inhibitors (ACEI) and Angiotensin II Receptor Antagonists (ARAs) to prevent and / or treat gastrointestinal complications associated with Diabetes mellitus.

The preparation method comprises the following steps: preparing raw materials, namely preparing amlodipine besylate and benazepril hydrochloride as main materials, taking a filling agent, a disintegrating agent and a lubricating agent as auxiliary materials, adding starch into powdered sugar, then adding purified water, heating while mixing and stirring, and uniformly mixing, so as to obtain the amlodipine besylate benazepril capsule. The preparation method comprises the following steps: preparing a gelatinized starch slurry as an adhesive solution for later use, mixing, putting amlodipine besylate and benazepril hydrochloride raw materials into a mixer according to a ratio of 1: 4, carrying out primary mixing, adding the adhesive solution into the uniformly mixed material, and stirring while adding to prepare a soft material. The composition of amlodipine besylate and benazepril hydrochloride is adopted, and amlodipine can selectively inhibit calcium ions from transmembrane entry into smooth muscle cells and myocardial cells, so that vascular smooth muscles are relaxed, peripheral vascular resistance is reduced, blood pressure is reduced, and angiotensin I is inhibited from being converted into angiotensin II.

The invention discloses application of a CDC20 inhibitor in preparation of a medicine for preventing or treating aortic dissection, and belongs to the field of biological medicine. A mouse aortic dissection model is constructed by combining 3-aortic acid aminopropionitrile ester with angiotensin II, a CDC20 inhibitor Apcin is given for treatment, and experiments find that by inhibiting CDC20 activity through Apcin, the occurrence rate and the lesion area of the mouse aortic dissection can be remarkably reduced, the vascular degenerative change in the lesion of the mouse aortic dissection can be remarkably improved, and the mouse aortic dissection model can be used for treating the aortic dissection of the mouse. Inflammatory macrophage infiltration in the aortic dissection lesion of the mouse is also obviously reduced; the results show that the mouse aortic dissection process can be delayed by inhibiting CDC20. The CDC20 inhibitor (Apcin or similar drugs) is further researched and optimized, so that a novel treatment drug for the aortic dissection is expected to be developed, and the CDC20 inhibitor has important significance in improving early intervention and prognosis of clinical aortic dissection patients.

The invention relates to a probiotic composite product helpful for inhibiting the activity of angiotensin and a preparation method thereof. The probiotic composite product contains lactobacillus plantarum CW006 and radix puerariae powder. Different from the prior art, the lactobacillus plantarum CWO06 added in the formula of the technical scheme can hydrolyze protein through extracellular protease, reduce conversion from angiotensin I to angiotensin II and reduce hydrolysis inactivation of bradykinin, so that the effect of reducing blood pressure is achieved. The radix puerariae powder serving as an active ingredient is rich in isoflavone substances, has an inhibiting effect on a renin-angiotensin system (RAS), and has an effect of assisting in lowering blood pressure.

The application discloses a kind of dual targeting / drug-loaded reduction-sensitive nano-carrier, and the micelle is formed by the micelle of block polymer by solvent evaporation method, and the multi-block polymer is Tel-PEG-ss-PCL, the hydrophilic end of which is PEG with targeting group Tel, and the hydrophobic end is PCL, which is a core-shell structure, the core is the hydrophobic end PCL, and the shell is the hydrophilic block with targeting group Tel.The nano-carrier selects the polymer micelle with hydrophilic end polyethylene glycol and hydrophobic end polycaprolactone as drug carrier to improve the problem of poor water solubility of drug;Tel, an angiotensin II type receptor (AT1R) ligand, is used to simultaneously target CAFs and tumor cells overexpressing AT1R, kill tumor cells and CAFs, and double drug loading to overcome drug resistance;Meanwhile, disulfide bond is used to respond to high concentration glutathione (GSH) in tumor cells to achieve precise control release of drug in cells.The nano-carrier realizes the treatment effect of solubilization of poorly soluble drug, tumor and CAFs dual targeting and reversal of drug resistance.

Use of darutoside in preparing a drug for preventing and treating hereditary hypertrophic cardiomyopathy. The darutoside is used for directly treating hypertrophic cardiomyocytes in vitro. It is found that the darutoside significantly reduces the area of cardiomyocytes, and reduces the increase of myocardial hypertrophy marker expression caused by angiotensin II; meanwhile, feed containing the darutoside is applied to feed Tnnt2R109Q mice, such that the weight of the left ventricle and heart of the mice is reduced, the heart volume and the thickness of the myocardial wall during diastole and systole are reduced, and myocardial tissue fibrosis of the mice with hypertrophic cardiomyopathy is effectively inhibited. The darutoside can be used for preparing a drug for preventing and treating hereditary hypertrophic cardiomyopathy and provides a new way and means for treating hypertrophic cardiomyopathy.

The application belongs to the technical field of biological medicine, and particularly relates to application of SFRP1 in treatment of aortic aging drugs. SFRP1 can induce generation of vascular organoids, significantly antagonize vascular smooth muscle cell senescence induced by angiotensin II and bleomycin, enhance vascular smooth muscle cell activity, improve cell oxidative stress ability, reduce cell beta-galactosidase activity, reduce intracellular calcium deposition level, reduce phenotype conversion and reduce extracellular matrix remodeling. Taxifolin can significantly improve accelerated aortic aging in VSMC-specific Sfrp1 knockout mice. SFRP1 and / or Taxifolin both play an anti-aortic aging role, prevent and / or treat aortic aging related diseases. SFRP1 can be used as a screening target to screen drugs against cell senescence damage.

The application discloses a chemical structural formula of a biphenyl sulfonamide compound of a bis-benzimidazole, and also discloses application of the compound in preparation of a pharmaceutically acceptable salt or solvate, application of the compound and the pharmaceutically acceptable salt or solvate in preparation of a medicine for treating endothelin-dependent or angiotensin II-dependent diseases. Meanwhile, the biphenyl sulfonamide compound of the bis-benzimidazole can also be used in combination by changing substituted functional groups. The biphenyl sulfonamide compound of the bis-benzimidazole, the prepared pharmaceutically acceptable salt or solvate and the medicine prepared by the compound have pharmacological activities, and have pharmacological effects in animals including human beings, and are particularly useful in treatment or prevention of IgA nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, chronic kidney disease, diabetic nephropathy, hypertension, coronary heart disease and myocardial infarction.

The invention belongs to the field of medicines, and particularly relates to a bacterial-derived ACE inhibitory peptide and application thereof. The ACE inhibitor is a novel peptide, is named as PVQRFF, has remarkable ACE inhibitory activity, and can effectively reduce the level of angiotensin II so as to achieve the purpose of controlling blood pressure. The PVQRFF has the potential application value in hypertension prevention and treatment by reducing blood pressure, improving blood circulation and protecting the cardiovascular system.

The present invention provides pharmaceutical compounds of formula I wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have the meanings given in the specification, which are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases such as idiopathic pulmonary fibrosis and sarcoidosis. # imgabs0 #

The application discloses application of isobutyrate in construction of a heart failure cell model and relates to the technical field of biology.The application constructs a new heart failure cell model by innovatively applying isobutyric acid or isobutyrate.The model can efficiently induce a heart failure phenotype by treating myocardial cells with 0.5-5 mM concentration of isobutyrate, wherein the effect of 5 mM concentration is optimal, can stably up-regulate the expression of core heart failure marker genes such as Nppa, Nppb and Myh7, and can significantly increase the myocardial cell area, which is consistent with the pathological characteristics of heart failure.Compared with a traditional neurohormone type such as angiotensin II, the application provides a novel heart failure cell model construction path which is not dependent on neurohormones, focuses on metabolic disorder related heart failure inducement, and makes up for the defect of single mechanism of an existing model, and provides a unique tool for research on myocardial injury caused by metabolic abnormalities or intestinal flora metabolites.

The application discloses a plant extraction compound for reducing blood pressure, a preparation method and application thereof. The compound is composed of high-purity silybin extract and a specific fusion polypeptide through molecular self-assembly. The sequence of the fusion polypeptide is shown in sequence SEQ ID NO:1, which innovatively integrates cell membrane penetration function, angiotensin II receptor 1 antagonism function and hydrophobic drug binding function. The core of the application is that through polypeptide-mediated active targeting, silybin is accurately delivered to the diseased blood vessel area, and the double synergistic mechanism of upstream ACE inhibition and downstream receptor blocking of the renin-angiotensin-aldosterone system is realized. In-vivo pharmacodynamic experiments prove that compared with single components, the compound can produce more significant and persistent antihypertensive effect, and can effectively reverse myocardial hypertrophy and fibrosis caused by hypertension, and show excellent synergistic therapeutic effect and target organ protection ability.

The invention relates to the technical field of activity detection, and particularly discloses a colloidal gold method for rapidly detecting ACE inhibitory activity and a test paper preparation method. The test paper comprises a sample pad, a gold-labeled pad, a nitrocellulose membrane and a water absorption pad, angiotensin converting enzyme labeled by colloidal gold is loaded on the gold-labeled pad, and a detection line coated with an angiotensin II antibody and a quality control line coated with an anti-ACE antibody are arranged on the nitrocellulose membrane. During detection, an ACE inhibitor in a sample can inhibit enzyme activity and influence aggregation of colloidal gold on the detection line, so that rapid judgment is realized through color comparison of the detection line and the quality control line. The invention also provides a preparation method and a detection method of the test paper, and the test paper has the advantages of simplicity and rapidness in operation, no need of large instruments, low cost, suitability for field detection and the like, and can be widely applied to drug screening, food detection and clinical sample preliminary screening.

The invention provides a composition based on elderberry and application of the composition to elimination of pulmonary nodules. The composition is prepared from an elderberry extract, a radix salviae miltiorrhizae extract, a sophora flower bud extract, beta-glucan, menthol and curcumin. The composition provided by the invention carries multiple components, multiple targets and multiple regulatory pathways to interact in a preparation. On one hand, the composition can inhibit generation and release of inflammatory factors by regulating oxidative stress, and on the other hand, the composition can prevent and eliminate pulmonary nodules by blocking generation of angiotensin II, inhibiting vascular hyperplasia and inflammatory response and regulating immunosuppression inflammation. The oral preparation described in the invention can be a drug loading system such as a capsule, a tablet, a granule, a suspension or an emulsion.

The invention discloses application of a membrane-bound O-acyltransferase structural domain 7 (Mboat7) in preparation of a medicine for treating myocardial hypertrophy, and belongs to the technical field of biology. Research results show that in a mouse cardiac hypertrophy model, compared with a control group mouse, heart weight / body weight, lung weight / body weight, cardiac muscle cell cross sectional area and fibrosis of a cardiac muscle cell specific Mboat7 gene overexpressed mouse are all remarkably reduced, and the cardiac systolic function is remarkably improved; the overexpressed Mboat7 gene can relieve isolated cell myocardial hypertrophy induced by angiotensin II. Particularly, overexpression of the Mboat7 gene can improve damage of mitochondria in myocardial tissue of a cardiac hypertrophy mouse. The results show that the Mboat7 gene overexpression relieves the disease progress of the pathological cardiac hypertrophy, and the Mboat7 or the expression promoter thereof can be used for preparing the medicine for preventing, relieving and / or treating the pathological cardiac hypertrophy.

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance / diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).

The present invention "Pharmaceutical use of RP11‑544D21.2, use in the preparation of anti-heart failure drugs, drugs and preparation methods" belongs to the field of biomedicine. The present invention provides the pharmaceutical use of RP11‑544D21.2, and the use of RP11‑544D21.2 in the preparation of anti-heart failure drugs or the preparation of heart failure animal models. The present invention further provides a new anti-heart failure drug targeting RP11‑544D21.2. Based on RP11‑544D21.2, the present invention also provides a screening method and a preparation method for anti-heart failure drugs, as well as a method for preparing a heart failure animal model. The experiments of the present invention confirm that knocking down RP11‑544D21.2 can inhibit the proliferation of fibroblasts and alleviate angiotensin II-induced differentiation into myofibroblasts. Animal experiments suggest that it is expected to improve cardiac function and alleviate cardiac remodeling.

This invention belongs to the field of molecular diagnostics, specifically relating to the application of miR-300-3p detection reagents in the preparation of products for diagnosing Ang II-mediated myocardial hypertrophy. The sequence of miR-300-3p is shown in SEQ ID NO.1. This invention, by detecting the expression level of miR-300-3p in myocardial tissue and cardiomyocytes, and through bioinformatics analysis and dual-luciferase reporter gene analysis, identifies ACOX1 as the direct target of miR-300-3p. Therefore, this invention elucidates the role of miR-300-3p in an angiotensin II-induced myocardial hypertrophy model, and the upregulation of miR-300-3p promotes myocardial hypertrophy by targeting ACOX1, providing a theoretical basis for future molecular-level diagnosis of myocardial hypertrophy, and possessing significant theoretical importance and potential practical value.